Legend Biotech Corp (LEGN) Non-Current Deffered Revenue (2019 - 2023)
Legend Biotech (LEGN) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $48.0 million as the latest value for Q4 2023.
- For the quarter ending Q4 2023, Non-Current Deffered Revenue changed N/A year-over-year to $48.0 million, compared with a TTM value of $48.0 million through Dec 2023, changed N/A, and an annual FY2023 reading of $48.0 million, changed N/A over the prior year.
- Non-Current Deffered Revenue was $48.0 million for Q4 2023 at Legend Biotech, down from $242.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $277.8 million in Q4 2019 and bottomed at $48.0 million in Q4 2023.
- Average Non-Current Deffered Revenue over 4 years is $210.8 million, with a median of $258.8 million recorded in 2020.
- The sharpest move saw Non-Current Deffered Revenue decreased 0.97% in 2020, then dropped 11.81% in 2021.
- Year by year, Non-Current Deffered Revenue stood at $277.8 million in 2019, then dropped by 0.97% to $275.1 million in 2020, then fell by 11.81% to $242.6 million in 2021, then crashed by 80.23% to $48.0 million in 2023.
- Business Quant data shows Non-Current Deffered Revenue for LEGN at $48.0 million in Q4 2023, $242.6 million in Q4 2021, and $275.1 million in Q4 2020.